Inhibition of cholesterol absorption: Targeting the intestine

Pharmaceutical Research

Volumn 29, Issue 12, 2012, Pages 3235-3250

  Lee, Stephen D ^a   Gershkovich, Pavel ^a,b   Darlington, Jerald W ^c   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c AMCOL International Corp   (United States)

Author keywords

Absorption; Atherosclerosis; Cholesterol; Heart disease; Targeted therapy

Indexed keywords

ALUMINUM SILICATE; ANTISENSE OLIGONUCLEOTIDE; AVASIMIBE; BAY 13 9953; BILE ACID SEQUESTRANT; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; DISODIUM ASCORBYL PHYTOSTANOL PHOSPHATE; EZETIMIBE; FM VP 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMPLITAPIDE; JTT 130; LIVER X RECEPTOR AGONIST; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; PACTIMIBE; PHYTOSTEROL; PLACEBO; SIMVASTATIN; SLX 4090; SMALL INTERFERING RNA; STANOL ESTER; SUCROSE POLYESTER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AORTA ATHEROSCLEROSIS; ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DIETARY FIBER; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INTESTINE ABSORPTION; LIPID ABSORPTION; MONOTHERAPY; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; RNA INTERFERENCE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; AZETIDINES; BILE ACIDS AND SALTS; CHOLESTEROL; HEART DISEASES; HUMANS; INTESTINAL ABSORPTION; MOLECULAR TARGETED THERAPY; ORPHAN NUCLEAR RECEPTORS; PHYTOSTEROLS; STEROL O-ACYLTRANSFERASE; TRANSCRIPTION, GENETIC;

EID: 84872061992     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0858-6     Document Type: Review

References (223)

1. Fuster V, Kelly BB, Vedanthan R. Global cardiovascular health: urgent need for an intersectoral approach. J Am Coll Cardiol. 2011;58(12):1208-10.
2. World Health Organization. Global burden of disease. Geneva: World Health Organization Press; 2008. p. 1-160.
3. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-25.
4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. (Pubitemid 39208455)
5. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and longterm coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274(2):131-6.
6. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823-8. (Pubitemid 17178359)
7. Keys A. Coronary heart disease in seven countries. I. The study program and objectives. Circulation. 1970;41(4 Suppl):I1-8.
8. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTER-HEART study): a case-control study. Lancet. 2008;372(9634):224-33. (Pubitemid 351978112)
9. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251(3):351-64.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
11. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170, 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
12. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
13. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009;25(10):567-79.
14. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011. p. 1769-818.
15. O'Neill FH, Patel DD, Knight BL, Neuwirth CK, Bourbon M, Soutar AK, et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2001;21(5):832-7. (Pubitemid 32448775)
16. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol. 2004;15(4):413-22. (Pubitemid 39061621)
17. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(23 Suppl 1):III50-7. (Pubitemid 38786444)
18. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565-81. (Pubitemid 44908269)
19. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681-90. (Pubitemid 37430274)
20. Matthan NR, Resteghini N, Robertson M, Ford I, Shepherd J, Packard C, et al. Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial. J Lipid Res. 2010;51(1):202-9.
21. Miettinen TA, Gylling H. Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup. Atherosclerosis. 2003;168(2):343-9. (Pubitemid 36703334)
22. Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur J Clin Invest. 2003;33(11):976-82. (Pubitemid 37421596)
23. Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106(15):1943-8. (Pubitemid 35176299)
24. Lin X, Racette SB, Lefevre M, Ma L, Spearie CA, Steger-May K, et al. Combined effects of ezetimibe and phytosterols on cholesterol metabolism: a randomized, controlled feeding study in humans. Circulation. 2011;124(5):596-601.
25. Kastelein JJP, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J. 2005;149(2):234-9. (Pubitemid 40348528)
26. Bosner MS, Lange LG, Stenson WF, Ostlund RE. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res. 1999;40(2):302-8. (Pubitemid 29069805)
27. Kern F. Normal plasma cholesterol in an 88-year-old man who eats 25 eggs a day. Mechanisms of adaptation. N Engl J Med. 1991;324(13):896-9.
28. Kesäniemi YA, Miettinen TA. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest. 1987;17(5):391-5. (Pubitemid 18063904)
29. Ostlund RE, Bosner MS, Stenson WF. Cholesterol absorption efficiency declines at moderate dietary doses in normal human subjects. J Lipid Res. 1999;40(8):1453-8. (Pubitemid 29379985)
30. Sehayek E. Genetic regulation of cholesterol absorption and plasma plant sterol levels: commonalities and differences. J Lipid Res. 2003;44(11):2030-8. (Pubitemid 37509618)
31. Kern F. Effects of dietary cholesterol on cholesterol and bile acid homeostasis in patients with cholesterol gallstones. J Clin Invest. 1994;93(3):1186-94.
32. Grundy SM, Metzger AL. A physiological method for estimation of hepatic secretion of biliary lipids in man. Gastroenterology. 1972;62(6):1200-17.
33. Wang DQ-H. Regulation of intestinal cholesterol absorption. Annu Rev Physiol. 2007;69:221-48. (Pubitemid 46457642)
34. Turley SD, Dietschy JM. Sterol absorption by the small intestine. Curr Opin Lipidol. 2003;14(3):233-40. (Pubitemid 36688201)
35. Piironen V, Lindsay D, Miettinen T, Toivo J, Lampi A. Plant sterols: biosynthesis, biological function and their importance to human nutrition. J Sci Food Agr. 2000;80(7):939-66. (Pubitemid 30319392)
36. Dutta P, Appelqvist L. Saturated sterols (stanols) in unhydrogenated and hydrogenated edible vegetable oils and in cereal lipids. J Sci Food Agr. 1996;71(3):383-91. (Pubitemid 26311777)
37. Shoenheimer R. New Contributions in sterol metabolism. Science. 1928;74:579-84.
38. Salen G, Ahrens EH, Grundy SM. Metabolism of beta-sitosterol in man. J Clin Invest. 1970;49(5):952-67.
39. Calpe-Berdiel L, Escolà-Gil JC, Blanco-Vaca F. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis. 2009;203(1):18-31.
40. Ling WH, Jones PJ. Dietary phytosterols: a review of metabolism, benefits and side effects. Life Sci. 1995;57(3):195-206.
41. Ostlund RE, McGill JB, Zeng C-M, Covey DF, Stearns J, Stenson WF, et al. Gastrointestinal absorption and plasma kinetics of soy Delta (5)-phytosterols and phytostanols in humans. Am J Physiol Endocrinol Metab. 2002;282(4):E911-6. (Pubitemid 34654753)
42. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771-5. (Pubitemid 32004809)
43. Berge KE, Von Bergmann K, Lutjohann D, Guerra R, Grundy SM, Hobbs HH, et al. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res. 2002;43(3):486-94. (Pubitemid 34252279)
44. Yu L, Von Bergmann K, Lutjohann D, Hobbs HH, Cohen JC. Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J Lipid Res. 2004;45(2):301-7. (Pubitemid 38228828)
45. Best MM, Duncan CH, van Loon EJ, Wathen JD. Lowering of serum cholesterol by the administration of a plant sterol. Circulation. 1954;10(2):201-6.
46. Pollak OJ. Reduction of blood cholesterol in man. Circulation. 1953;7(5):702-6.
47. Sudhop T, Bergmann VK. Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs. 2002;62(16):2333-47. (Pubitemid 35316384)
48. Cater NB, Garcia-Garcia A-B, Vega GL, Grundy SM. Responsiveness of plasma lipids and lipoproteins to plant stanol esters. Am J Cardiol. 2005;96(1A):23D-8D. (Pubitemid 40898166)
49. Ikeda I, Sugano M. Inhibition of cholesterol absorption by plant sterols for mass intervention. Curr Opin Lipidol. 1998;9(6):527-31. (Pubitemid 29041446)
50. Heinemann T, Kullak-Ublick GA, Pietruck B, von Bergmann K. Mechanisms of action of plant sterols on inhibition of cholesterol absorption. Comparison of sitosterol and sitostanol. Eur J Clin Pharmacol. 1991;40 Suppl 1:S59-63.
51. Sugano M, Morioka H, Ikeda I. A comparison of hypocholesterolemic activity of beta-sitosterol and beta-sitostanol in rats. J Nutr. 1977;107(11):2011-9. (Pubitemid 8205901)
52. Heinemann T, Axtmann G, von Bergmann K. Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur J Clin Invest. 1993;23(12):827-31. (Pubitemid 24015625)
53. Weingärtner O, Ulrich C, Lutjohann D, Ismail K, Schirmer SH, Vanmierlo T, et al. Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE-/-mice. Cardiovasc Res. 2011;90(3):484-92.
54. Demonty I, Ras RT, van der Knaap HCM, Duchateau GSMJE, Meijer L, Zock PL, et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr. 2009;139(2):271-84.
55. Jones PJH. Dietary agents that target gastrointestinal and hepatic handling of bile acids and cholesterol. J Clin Lipidol. 2008;2(2):S4-S10. (Pubitemid 351372947)
56. Wasan KM, Najafi S, Wong J, Kwong M, Pritchard PH. Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharm Sci. 2001;4(3):228-34. (Pubitemid 34305598)
57. Wasan KM, Najafi S, Peteherych KD, Pritchard PH. Effects of a novel hydrophilic phytostanol analog on plasma lipid concentrations in gerbils. J Pharm Sci. 2001;90(11):1795-9. (Pubitemid 33062600)
58. Ramaswamy M, Yau E, Wasan KM, Boulanger KD, Li M, Pritchard PH. Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. J Pharm Pharm Sci. 2002;5(1):29-38.
59. Méndez-González J, Süren-Castillo S, Calpe-Berdiel L, Rotllan N, Vázquez-Carrera M, Escolà-Gil JC, et al. Disodium ascorbyl phytostanol phosphate (FM-VP4), a modified phytostanol, is a highly active hypocholesterolaemic agent that affects the enterohepatic circulation of both cholesterol and bile acids in mice. Br J Nutr. 2010;103(2):153-60.
60. Lukic T, Wasan KM, Zamfir D, Moghadasian MH, Pritchard PH. Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice. Metab Clin Exp. 2003;52(4):425-31. (Pubitemid 36773263)
61. Looije NA, Risovic V, Stewart DJ, Debeyer D, Kutney J, Wasan KM. Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model. J Pharm Pharm Sci. 2005;8(3):400-8. (Pubitemid 41529319)
62. Thornton SJ, Warburton C, Wasan KM, Kozlowski P. Treatment with a cholesterol absorption inhibitor (FM-VP4) reduces body mass and adipose accumulation in developing and preobese mice. Drug Dev Ind Pharm. 2007;33(10):1058-69. (Pubitemid 350034838)
63. Ebine N, Jia X, Demonty I, Wang Y, Jones PJH. Effects of a water-soluble phytostanol ester on plasma cholesterol levels and red blood cell fragility in hamsters. Lipids. 2005;40(2):175-80. (Pubitemid 40530222)
64. Vissers MN, Trip MD, Pritchard PH, Tam P, Lukic T, de Sainvan der Velden MG, et al. Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia. Eur J Clin Pharmacol. 2008;64(7):651-61.
65. Gylling H, Miettinen TA. The effect of plant stanol-and sterolenriched foods on lipid metabolism, serum lipids and coronary heart disease. Ann Clin Biochem. 2005;42(Pt 4):254-63. (Pubitemid 40961742)
66. Armstrong MJ, Carey MC. Thermodynamic and molecular determinants of sterol solubilities in bile salt micelles. J Lipid Res. 1987;28(10):1144-55.
67. Ikeda I, Tanaka K, Sugano M, Vahouny GV, Gallo LL. Inhibition of cholesterol absorption in rats by plant sterols. J Lipid Res. 1988;29(12):1573-82. (Pubitemid 19030525)
68. Ikeda I, Tanabe Y, Sugano M. Effects of sitosterol and sitostanol on micellar solubility of cholesterol. J Nutr Sci Vitaminol. 1989;35(4):361-9. (Pubitemid 19268727)
69. Amiot MJ, Knol D, Cardinault N, Nowicki M, Bott R, Antona C, et al. Phytosterol ester processing in the small intestine: impact on cholesterol availability for absorption and chylomicron cholesterol incorporation in healthy humans. J Lipid Res. 2011;52(6):1256-64.
70. Kaneko E, Matsuda M, Yamada Y, Tachibana Y, Shimomura I, Makishima M. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J Biol Chem. 2003;278(38):36091-8. (Pubitemid 37139930)
71. Plat J, Nichols JA, Mensink RP. Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation. J Lipid Res. 2005;46(11):2468-76. (Pubitemid 41532535)
72. Calkin AC, Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(8):1513-8.
73. Batta AK, Xu G, Honda A, Miyazaki T, Salen G. Stigmasterol reduces plasma cholesterol levels and inhibits hepatic synthesis and intestinal absorption in the rat. Metab Clin Exp. 2006;55(3):292-9. (Pubitemid 43234381)
74. Jesch ED, Seo JM, Carr TP, Lee J-Y. Sitosterol reduces messenger RNA and protein expression levels of Niemann-Pick C1-like 1 in FHs 74 Int cells. Nutr Res. 2009;29(12):859-66.
75. Field FJ, Born E, Mathur SN. Effect of micellar beta-sitosterol on cholesterol metabolism in CaCo-2 cells. J Lipid Res. 1997;38(2):348-60. (Pubitemid 27118047)
76. Field FJ, Born E, Mathur SN. Stanol esters decrease plasma cholesterol independently of intestinal ABC sterol transporters and Niemann-Pick C1-like 1 protein gene expression. J Lipid Res. 2004;45(12):2252-9. (Pubitemid 39602972)
77. Gylling H, Miettinen TA. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men. J Lipid Res. 1996;37(8):1776-85. (Pubitemid 26275389)
78. Russell DW. Nuclear orphan receptors control cholesterol catabolism. Cell. 1999;97(5):539-42. (Pubitemid 29256955)
79. Chawla A, Saez E, Evans RM. Don't know much bile-ology. Cell. 2000;103(1):1-4.
80. Hou R, Goldberg AC. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am. 2009;38(1):79-97.
81. Insull W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99(3):257-73.
82. Wong NN. Colesevelam: a new bile acid sequestrant. Heart Dis. 2001;3(1):63-70. (Pubitemid 33668862)
83. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159(16):1893-900. (Pubitemid 29424709)
84. Insull W, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001;76(10):971-82. (Pubitemid 32946008)
85. Kerr TA, Saeki S, Schneider M, Schaefer K, Berdy S, Redder T, et al. Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. Dev Cell. 2002;2(6):713-20. (Pubitemid 34650068)
86. Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol. 1990;30(2):99-106. (Pubitemid 20143335)
87. Grundy SM, Ahrens EH, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 1971;78(1):94-121.
88. Garbutt JT, Kenney TJ. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest. 1972;51(11):2781-9.
89. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci U S A. 1983;80(13):4124-8.
90. Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 2008;8(6):512-21.
91. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol. 2006;97(8):1198-205.
92. Schwarz M, Russell DW, Dietschy JM, Turley SD. Alternate pathways of bile acid synthesis in the cholesterol 7alphahydroxylase knockout mouse are not upregulated by either cholesterol or cholestyramine feeding. J Lipid Res. 2001;42(10):1594-603. (Pubitemid 33020091)
93. Repa JJ, Lund EG, Horton JD, Leitersdorf E, Russell DW, Dietschy JM, et al. Disruption of the sterol 27-hydroxylase gene in mice results in hepatomegaly and hypertriglyceridemia. Rezversal by cholic acid feeding. J Biol Chem. 2000;275(50):39685-92. (Pubitemid 32058997)
94. Fujihashi T, Munekiyo K, Meshi T. Effects of colestipol hydrochloride on cholesterol and bile acids absorption in the rat intestinal tract. J Pharmacobiodyn. 1981;4(8):552-8. (Pubitemid 11011487)
95. Takahashi M, Sarwal AN, Raicht RF, Cohen BI. Effect of colestipol on sterol metabolism in the rat. Lipids. 1980;15(6):434-8. (Pubitemid 11226873)
96. Briones ER, Steiger D, Palumbo PJ, Kottke BA. Primary hypercholesterolemia: effect of treatment on serum lipids, lipoprotein fractions, cholesterol absorption, sterol balance, and platelet aggregation. Mayo Clin Proc. 1984;59(4):251-7. (Pubitemid 14138131)
97. Miettinen TA, Lempinen M. Cholestyramine and ileal by-pass in the treatment of familial hypercholesterolaemia. Eur J Clin Invest. 1977;7(6):509-14. (Pubitemid 8283559)
98. Donovan JM, von Bergmann K, Setchell KDR, Isaac sohn J, Pappu AS, Illingworth DR, et al. Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia. Dig Dis Sci. 2005;50(7):1232-8. (Pubitemid 41184748)
99. McNamara DJ, Davidson NO, Samuel P, Ahrens EH. Cholesterol absorption in man: effect of administration of clofibrate and/or cholestyramine. J Lipid Res. 1980;21(8):1058-64. (Pubitemid 11183168)
100. Crouse JR. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med. 1987;83(2):243-8.
101. Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, Oosterveer MH, et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor-and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology. 2010;51(3):806-16.
102. Bays HE, Goldberg RB. The "forgotten" bile acid sequestrants: is now a good time to remember? Am J Ther. 2007;14(6):567-80. (Pubitemid 350307694)
103. Wang DQ, Lammert F, Cohen DE, Paigen B, Carey MC. Cholic acid aids absorption, biliary secretion, and phase transitions of cholesterol in murine cholelithogenesis. Am J Physiol. 1999;276(3 Pt 1):G751-60. (Pubitemid 29157442)
104. Wang DQ-H, Tazuma S, Cohen DE, Carey MC. Feeding natural hydrophilic bile acids inhibits intestinal cholesterol absorption: studies in the gallstone-susceptible mouse. Am J Physiol Gastrointest Liver Physiol. 2003;285(3):G494-502. (Pubitemid 37021809)
105. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol. 2000;86(12A):35L-40L.
106. Lewis MC, Brieaddy LE, Root C. Effects of 2164U90 on ileal bile acid absorption and serum cholesterol in rats and mice. J Lipid Res. 1995;36(5):1098-105.
107. Kitayama K, Nakai D, Kono K, van der Hoop AG, Kurata H, de Wit EC, et al. Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. Eur J Pharmacol. 2006;539(1-2):89-98. (Pubitemid 44208810)
108. Vahouny GV, Tombes R, Cassidy MM, Kritchevsky D, Gallo LL. Dietary fibers: V. Binding of bile salts, phospholipids and cholesterol from mixed micelles by bile acid sequestrants and dietary fibers. Lipids. 1980;15(12):1012-8. (Pubitemid 11149443)
109. Gershkovich P, Sivak O, Contreras-Whitney S, Darlington JW, Wasan KM. Assessment of cholesterol absorption inhibitors nanostructured aluminosilicate and cholestyramine using in vitro lipolysis model. J Pharm Sci. 2012;101(1):291-300.
110. Cummings JH, Mann JI, Nishida C, Vorster HH. Dietary fibre: an agreed definition. Lancet. 2009;373(9661):365-6.
111. Pereira MA, O'Reilly E, Augustsson K, Fraser GE, Goldbourt U, Heitmann BL, et al. Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med. 2004;164(4):370-6. (Pubitemid 38240700)
112. Anderson JW, Baird P, Davis RH, Ferreri S, Knudtson M, Koraym A, et al. Health benefits of dietary fiber. Nutr Rev. 2009;67(4):188-205.
113. Streppel MT, Ocké MC, Boshuizen HC, Kok FJ, Kromhout D. Dietary fiber intake in relation to coronary heart disease and allcause mortality over 40 y: the Zutphen Study. Am J Clin Nutr. 2008;88(4):1119-25.
114. Kromhout D, Bosschieter EB, de Lezenne Coulander C. Dietary fibre and 10-year mortality from coronary heart disease, cancer, and all causes. The Zutphen study. Lancet. 1982;8297(2):518-22. (Pubitemid 12048145)
115. Khaw KT, Barrett-Connor E. Dietary fiber and reduced ischemic heart disease mortality rates in men and women: a 12-year prospective study. Am J Epidemiol. 1987;126(6):1093-102. (Pubitemid 18017795)
116. Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA. 1996;275(6):447-51. (Pubitemid 26065617)
117. Van Horn L. Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997;95(12):2701-4. (Pubitemid 27255501)
118. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterollowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30-42. (Pubitemid 29031248)
119. Turner PR, Tuomilehto J, Happonen P, La Ville AE, Shaikh M, Lewis B. Metabolic studies on the hypolipidaemic effect of guar gum. Atherosclerosis. 1990;81(2):145-50. (Pubitemid 20098745)
120. Kay RM, Truswell AS. Effect of citrus pectin on blood lipids and fecal steroid excretion in man. Am J Clin Nutr. 1977;30(2):171-5. (Pubitemid 8036594)
121. Simons LA, Gayst S, Balasubramaniam S, Ruys J. Long-term treatment of hypercholesterolaemia with a new palatable formulation of guar gum. Atherosclerosis. 1982;45(1):101-8. (Pubitemid 13237674)
122. Levrat-Verny MA, Behr S, Mustad V, Rémésy C, Demigné C. Low levels of viscous hydrocolloids lower plasma cholesterol in rats primarily by impairing cholesterol absorption. J Nutr. 2000;130(2):243-8. (Pubitemid 30073802)
123. Miettinen TA, Tarpila S. Serum lipids and cholesterol metabolism during guar gum, plantago ovata and high fibre treatments. Clin Chim Acta. 1989;183(3):253-62. (Pubitemid 19219220)
124. Davidson NO, Magun AM, Brasitus TA, Glickman RM. Intestinal apolipoprotein A-I and B-48 metabolism: effects of sustained alterations in dietary triglyceride and mucosal cholesterol flux. J Lipid Res. 1987;28(4):388-402. (Pubitemid 17055551)
125. Turley SD, Herndon MW, Dietschy JM. Reevaluation and application of the dual-isotope plasma ratio method for the measurement of intestinal cholesterol absorption in the hamster. J Lipid Res. 1994;35(2):328-39. (Pubitemid 24050446)
126. Turley SD, Daggy BP, Dietschy JM. Psyllium augments the cholesterol-lowering action of cholestyramine in hamsters by enhancing sterol loss from the liver. Gastroenterology. 1994;107(2):444-52. (Pubitemid 24233319)
127. Crouse JR, Grundy SM, Johnson JH. Effects of AOMA on cholesterol metabolism in man. Metab Clin Exp. 1982;31(7):733-9. (Pubitemid 12070700)
128. Mattson FH, Jandacek RJ, Webb MR. The effect of a nonabsorbable lipid, sucrose polyester, on the absorption of dietary cholesterol by the rat. J Nutr. 1976;106(6):747-52.
129. Crouse JR, Grundy SM. Effects of sucrose polyester on cholesterol metabolism in man. Metab Clin Exp. 1979;28(10):994-1000. (Pubitemid 10201197)
130. Mellies MJ, Jandacek RJ, Taulbee JD, Tewksbury MB, Lamkin G, Baehler L, et al. A double-blind, placebo-controlled study of sucrose polyester in hypercholesterolemic outpatients. Am J Clin Nutr. 1983;37(3):339-46. (Pubitemid 13086412)
131. Cai Y, Meng X-F, Cao Y-X, Lu H, Zhu S-F, Zhou L-Z. Montmorillonite ameliorates hyperthyroidism of rats and mice attributed to its adsorptive effect. Eur J Pharmacol. 2006;551(1-3):156-61. (Pubitemid 44648049)
132. Kocoshis SA, Ghent CN, Gryboski JD. In vitro bile acid adsorption by bismuth subsalicylate and montmorillonite. Dig Dis Sci. 1984;29(12):1148-52. (Pubitemid 15181484)
133. Gershkovich P, Darlington J, Sivak O, Constantinides PP, Wasan KM. Inhibition of intestinal absorption of cholesterol by surfacemodified nanostructured aluminosilicate compounds. J Pharm Sci. 2009;98(7):2390-400.
134. Sivak O, Darlington J, Gershkovich P, Constantinides PP, Wasan KM. Protonated nanostructured aluminosilicate (NSAS) reduces plasma cholesterol concentrations and atherosclerotic lesions in Apolipoprotein E deficient mice fed a high cholesterol and high fat diet. Lipids Health Dis. 2009;8:30.
135. Clader JW. The discovery of ezetimibe: a view from outside the receptor. J Med Chem. 2004;47(1):1-9. (Pubitemid 38040483)
136. Davis HR, Compton DS, Hoos L, Tetzloff G, Capelen MA, Burnett DA. Ezetimibe (SCH58235) localizes to the brush border of small intestinal enterocyte and inhibits entertocyte cholesterol uptake and absorption. Eur Heart J. 21(abstract supplement):636.
137. Graf GA, Li W-P, Gerard RD, Gelissen I, White A, Cohen JC, et al. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest. 2002;110(5):659-69. (Pubitemid 34988790)
138. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest. 2002;110(5):671-80. (Pubitemid 34988791)
139. Miettinen TA. Phytosterolaemia, xanthomatosis and premature atherosclerotic arterial disease: a case with high plant sterol absorption, impaired sterol elimination and low cholesterol synthesis. Eur J Clin Invest. 1980;10(1):27-35. (Pubitemid 10133847)
140. Patel SB, Salen G, Hidaka H, Kwiterovich PO, Stalenhoef AF, Miettinen TA, et al. Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. J Clin Invest. 1998;102(5):1041-4. (Pubitemid 28419249)
141. Altmann SW, Davis HR, Zhu L-J, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201-4. (Pubitemid 38233587)
142. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102(23):8132-7. (Pubitemid 40800055)
143. Ge L, Wang J, Qi W, Miao H-H, Cao J, Qu Y-X, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab. 2008;7(6):508-19. (Pubitemid 351729203)
144. Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol. 2008;9(2):125-38. (Pubitemid 351158918)
145. Petersen NH, Faergeman NJ, Faegeman NJ, Yu L, Wüstner D. Kinetic imaging of NPC1L1 and sterol trafficking between plasma membrane and recycling endosomes in hepatoma cells. J Lipid Res. 2008;49(9):2023-37.
146. Ge L, Qi W, Wang L-J, Miao H-H, Qu Y-X, Li B-L, et al. Flotillins play an essential role in Niemann-Pick C1-like 1-mediated cholesterol uptake. Proc Natl Acad Sci U S A. 2011;108(2):551-6.
147. Earl J, Kirkpatrick P. Fresh from the pipeline. Ezetimibe Nat Rev Drug Discov. 2003;2(2):97-8.
148. Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFH, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431-43. (Pubitemid 351482735)
149. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113-22.
150. Blumenthal RS, Michos ED. The HALTS trial-halting atherosclerosis or halted too early? N Engl J Med. 2009;361(22):2178-80.
151. Lindsay AC, Halcox JP. Niacin compared with ezetimibe. N Engl J Med. 2010;362(11):1046. authorreply1048.
152. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science. 2001;294(5548):1866-70. (Pubitemid 33101573)
153. Wilund KR, Yu L, Xu F, Hobbs HH, Cohen JC. High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr-/-mice. J Lipid Res. 2004;45(8):1429-36. (Pubitemid 39006970)
154. Yu L, York J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem. 2003;278(18):15565-70. (Pubitemid 36799664)
155. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7(5):365-75. (Pubitemid 351598023)
156. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14(22):2831-8.
157. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory elementbinding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000;14(22):2819-30.
158. Buhman KK, Accad M, Novak S, Choi RS, Wong JS, Hamilton RL, et al. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med. 2000;6(12):1341-7. (Pubitemid 32001017)
159. Repa JJ, Buhman KK, Farese RV, Dietschy JM, Turley SD. ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: impact on hepatic cholesterol homeostasis. Hepatology. 2004;40(5):1088-97. (Pubitemid 39425564)
160. Nguyen TM, Sawyer JK, Kelley KL, Davis MA, Rudel LL. Cholesterol esterification by ACAT2 is essential for efficient intestinal cholesterol absorption: evidence from thoracic lymph duct cannulation. J Lipid Res. 2012;53(1):95-104.
161. Anderson RA, Joyce C, Davis M, Reagan JW, Clark M, Shelness GS, et al. Identification of a form of acyl-CoA: cholesterol acyltransferase specific to liver and intestine in nonhuman primates. J Biol Chem. 1998;273(41):26747-54. (Pubitemid 28471691)
162. Oelkers P, Behari A, Cromley D, Billheimer JT, Sturley SL. Characterization of two human genes encoding acyl coenzyme A: cholesterol acyltransferase-related enzymes. J Biol Chem. 1998;273(41):26765-71. (Pubitemid 28471693)
163. Cases S, Novak S, Zheng YW, Myers HM, Lear SR, Sande E, et al. ACAT-2, a second mammalian acyl-CoA: cholesterol acyltransferase. Its cloning, expression, and characterization. J Biol Chem. 1998;273(41):26755-64.
164. Chang T-Y, Li B-L, Chang CCY, Urano Y. Acyl-coenzyme A: cholesterol acyltransferases. Am J Physiol Endocrinol Metab. 2009;297(1):E1-9.
165. Chang CC, Sakashita N, Ornvold K, Lee O, Chang ET, Dong R, et al. Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J Biol Chem. 2000;275(36):28083-92.
166. Lee O, Chang CC, Lee W, Chang TY. Immunodepletion experiments suggest that acyl-coenzyme A: cholesterol acyltransferase-1 (ACAT-1) protein plays a major catalytic role in adult human liver, adrenal gland, macrophages, and kidney, but not in intestines. J Lipid Res. 1998;39(8):1722-7. (Pubitemid 28377938)
167. Accad M, Smith SJ, Newland DL, Sanan DA, King LE, Linton MF, et al. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA: cholesterol acyltransferase 1. J Clin Invest. 2000;105(6):711-9. (Pubitemid 30164109)
168. Fazio S, Major AS, Swift LL, Gleaves LA, Accad M, Linton MF, et al. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest. 2001;107(2):163-71. (Pubitemid 32096832)
169. Tardif J-C, Grégoire J, L'Allier PL, Anderson TJ, Bertrand O, Reeves F, et al. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004;110(21):3372-7. (Pubitemid 39557502)
170. Sahi J, Milad MA, Zheng X, Rose KA, Wang H, Stilgenbauer L, et al. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J Pharmacol Exp Ther. 2003;306(3):1027-34. (Pubitemid 37025310)
171. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354(12):1253-63.
172. Rudel LL, Farese RV. ACAT inhibition and the progression of coronary atherosclerosis. N Engl J Med. 2006;354(24):2616-7. author reply 2616-7. (Pubitemid 43882368)
173. Zhang J, Kelley KL, Marshall SM, Davis MA, Wilson MD, Sawyer JK, et al. Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood. J Lipid Res. 2012 Mar. 29.
174. Ohshiro T, Ohte S, Matsuda D, Ohtawa M, Nagamitsu T, Sunazuka T, et al. Selectivity of pyripyropene derivatives in inhibition toward acyl-CoA: cholesterol acyltransferase 2 isozyme. J Antibiot. 2008;61(8):503-8.
175. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov. 2008;7(1):84-99.
176. Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258(5084):999-1001.
177. Wetterau JR, Gregg RE, Harrity TW, Arbeeny C, Cap M, Connolly F, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science. 1998;282(5389):751-4. (Pubitemid 28489389)
178. Robl JA, Sulsky R, Sun CQ, Simpkins LM, Wang T, Dickson JK, et al. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J Med Chem. 2001;44(6):851-6. (Pubitemid 32861609)
179. Funatsu T, Kakuta H, Takasu T, Miyata K. Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor. Eur J Pharmacol. 2002;455(2-3):161-7. (Pubitemid 35351610)
180. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003;44(10):1887-901. (Pubitemid 37356661)
181. Ellis JL, Bartolozzi A, Ferkany J, Foudoulakis H, Kim E, Kuo J, et al. SLx-4090, an enterocyte-specific microsomal triglyceride transport protein inhibitor, lowers LDL cholesterol and triglycerides while raising HDL cholesterol in Apo E -/- mice fed a highfat diet. Arterioscler Thromb Vasc Biol. 2007;27(6):64e.
182. Ueshima K, Akihisa-Umeno H, Nagayoshi A, Takakura S, Matsuo M, Mutoh S. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull. 2005;28(2):247-52. (Pubitemid 40880003)
183. Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, Fernandez ML. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord. 2005;5:30.
184. Mera Y, Odani N, Kawai T, Hata T, Suzuki M, Hagiwara A, et al. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'- trifluoromethylbiphenyl-2-carbonyl) amino]phenyl}acetyloxymethyl)-2- phenylmalonate (JTT-130), an intestinespecific inhibitor of microsomal triglyceride transfer protein. J Pharmacol Exp Ther. 2011;336(2):321-7.
185. Ksander GM, de Jesus R, Yuan A, Fink C, Moskal M, Carlson E, et al. Diaminoindanes as microsomal triglyceride transfer protein inhibitors. J Med Chem. 2001;44(26):4677-87. (Pubitemid 33144477)
186. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5(8):497-505.
187. Cuchel M, Meagher E, Marais AD, Blom DJ, Theron HD, Baer AL, et al. A Phase III Study of Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide (AEGR-733) in Patients With Homozygous Familial Hypercholesterolemia: Interim Results at 6 Months. Circulation. 2009;120(18):S441.
188. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356(2):148-56. (Pubitemid 46089675)
189. Lammens L, Borghys H, Roevens P, Vandenberghe J. Histological changes in liver and jejunum induced by R103757, a new inhibitor of microsomal triglyceride transfer protein (MTP). Atherosclerosis. Atherosclerosis. 1999;144:39.
190. Miyazaki K, Miwa S, Kodama H, Yamada H, Nagata K, Toriumi W, et al. Hepatic and intestinal changes in rats treated with T-0126, a microsomal triglyceride transfer protein (mtp) inhibitor. J Toxicol Sci. 2007;32(2):161-77. (Pubitemid 46849773)
191. Kim E, Campbell S, Schueller O, Wong E, Cole B, Kuo J, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011;337(3):775-85.
192. Guo Q, Avramoglu RK, Adeli K. Intestinal assembly and secretion of highly dense/lipid-poor apolipoprotein B48-containing lipoprotein particles in the fasting state: evidence for induction by insulin resistance and exogenous fatty acids. Metab Clin Exp. 2005;54(5):689-97. (Pubitemid 40585660)
193. Magun AM, Mish B, Glickman RM. Intracellular apoA-I and apoB distribution in rat intestine is altered by lipid feeding. J Lipid Res. 1988;29(9):1107-16.
194. Cartwright IJ, Plonné D, Higgins JA. Intracellular events in the assembly of chylomicrons in rabbit enterocytes. J Lipid Res. 2000;41(11):1728-39.
195. Cartwright IJ, Higgins JA. Direct evidence for a two-step assembly of ApoB48-containing lipoproteins in the lumen of the smooth endoplasmic reticulum of rabbit enterocytes. J Biol Chem. 2001;276(51):48048-57.
196. Ginsberg HN, Fisher EA. The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism. J Lipid Res. 2009;50:S162-6.
197. Fisher EA. The degradation of apolipoprotein B100: Multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways. Biochim. Biophys. Acta. 2012 Feb. 10.
198. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11(2):125-40.
199. Hannon GJ. RNA interference. Nature. 2002;418(6894):244-51. (Pubitemid 34773784)
200. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 2002;1(5):347-55.
201. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173-8. (Pubitemid 39545841)
202. Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441(7089):111-4.
203. Kastelein JJP, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114(16):1729-35. (Pubitemid 44607121)
204. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng M-J, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006.
205. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9.
206. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9. (Pubitemid 26338729)
207. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-22. (Pubitemid 28248586)
208. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339(19):1349-57.
209. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
210. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23):2998-3007.
211. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225-8. (Pubitemid 41615541)
212. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145(3):341-55.
213. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399-409.
214. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol. 2010;13(55):1283-99.
215. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69(2):313-24. (Pubitemid 14180337)
216. Drugs @ FDA [Internet]. United States Food and Drug Administration; [cited 2012 Jul. 5]. Available from: http://www.access data.fda.gov/scripts/ cder/drugsatfda/index.cfm
217. Gaw A, Packard CJ, Lindsay GM, Murray EF, Griffin BA, Caslake MJ, et al. Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1996;16(2):236-49. (Pubitemid 26056242)
218. Zema MJ. Add-on therapy for hypercholesterolemia: a pilot comparison of two gastrointestinally-acting agents in statintreated patients. J Clin Lipidol. 2009;3(2):119-24.
219. clinicaltrials.gov [Internet]. [cited 2012 Apr. 5]. Available from: http://www.clinicaltrials.gov
220. Rizzo M, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des. 2011;17(9):943-9.
221. Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UHW, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebocontrolled trial. Eur Heart J. 2012;33(9):1142-9.
222. Tardif J-C, McGowan M, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. Apolipoprotein B synthesis inhibition by mipomersen reduces LDL-C when added to maximally tolerated lipidlowering medication in patients with severe heterozygous hypercholesterolemia. J Am Coll Cardiol. 2011;57(14 Supplement 5):E492.
223. Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M. Safety and efficacy of mipomersen administered as add-on therapy in patients with hypercholesterolemia and high cardiovascular risk. J Am Coll Cardiol. 2011;57(14 Supplement 5):E504.